Insider Cluster (3 insiders) ·Filed May 20, 2026

REPL

Replimune Group, Inc.
NEUTRAL
Impact 4/10
Horizonimmediate Processed4mo ago
Insider cluster: 3 insiders, $0.3M total
Actionable Insight • Neutral

The identical execution price and date across CEO/CFO/director sales suggest a pre-arranged plan or blackout-window opening rather than reactive selling. At 0.08% of market cap, these volumes are noise. However, the CEO's sale of ~$190K is the largest single insider transaction in the trailing 30 days — monitor for any material 8-K or pipeline update within the next two weeks that might have prompted the timing.

DirectionNeutral
Confidencemedium
Horizonimmediate
Final — all horizons settled through T+60d
REPL ▲ +180.27% at T+60d
NEUTRAL call ✓ call won +180.27% · α vs SPY +175.97% · entry $5.22 → $14.63
Entry anchored
May 20, 2026
via day open
T+1d
-5.94%
call -5.94% · α -6.38%
$4.91
settled 4mo ago
T+5d
+66.48%
call +66.48% · α +64.63%
$8.69
settled 4mo ago
T+20d
+113.98%
call +113.98% · α +113.65%
$11.17
settled 4mo ago
T+60d
+180.27%
call +180.27% · α +175.97%
$14.63
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Three REPL insiders (CEO, CFO, and a director) sold a total of $319K in open-market sales on May 18, 2026, all at $5.08 per share. The CEO's sale of $190K is the largest, and the cluster timing is identical across all three, suggesting a coordinated or programmatic exit rather than opportunistic selling based on fresh negative information.

Key Financial Metrics

Direction
selling
Total Value
$319.0K
Insiders
3

Key Facts

  • CEO Patel Sushil sold 37,324 shares for $190K
  • CFO Hill Emily Luisa sold 7,812 shares for $40K
  • Director Astley-Sparke Philip sold 17,657 shares for $90K
  • All three trades executed at $5.08 on May 18, 2026
  • Total cluster value $319K represents 0.08% of $388M market cap
  • No open-market purchases in the cluster — all sales

Financial Impact

$319K total insider sales, below 0.1% of market cap — trivial relative to company size

insider ownershipfloat

Risk Factors

  • CEO sold the largest dollar amount — insider confidence signal worth tracking
  • No insider buying to offset the selling — one-sided signal
  • REPL has a 59% bearish analyst consensus — selling could amplify existing negative sentiment

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
8% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-REPL-1779308220177
20 reports for REPL
Performance horizon
76% Hit rate 13 of 17 directional calls best @ T+20▲ +188.35%Jul 30, 2026
Filters
Rows
Reports for REPL — sortable, filterable
TypeNow
Aug 21, 2026
5w ago
Press Release
BEARISH ★ 7/10
$14.71 $13.07▲ +11.15%▲ +11.16%$13.04 (+11.35%)
Aug 19, 2026
6w ago
Insider Cluster
MIXED ★ 6/10
$14.05 $13.07▼ −6.98%▼ −6.98%$13.04 (−7.19%)
Aug 14, 2026
7w ago
8-K
BULLISH ★ 7/10
$14.97 $13.11▼ −12.42%▼ −10.43%$13.04 (−12.89%)
Aug 14, 2026
7w ago
Press Release
BULLISH ★ 7/10
$14.97 $13.11▼ −12.42%▼ −10.43%$13.04 (−12.89%)
Aug 12, 2026
7w ago
Insider Cluster
MIXED ★ 6/10
$15.19 $12.92▼ −14.94%▼ −13.20%$13.04 (−14.15%)
Aug 12, 2026
7w ago
Insider Cluster
BULLISH ★ 7/10
$15.19 $12.92▼ −14.94%▼ −13.20%$13.04 (−14.15%)
Aug 10, 2026
7w ago
Press Release
BEARISH ★ 6/10
$13.67 $14.77▼ −8.05%▼ −8.96%$13.04 (+4.61%)
Aug 10, 2026
7w ago
8-K
BEARISH ★ 6/10
$13.67 $14.77▼ −8.05%▼ −8.96%$13.04 (+4.61%)
Aug 10, 2026
7w ago
424B5
BEARISH ★ 7/10
$13.67 $14.77▼ −8.05%▼ −8.96%$13.04 (+4.61%)
Aug 7, 2026
8w ago
8-K
BULLISH ★ 8/10
$12.06 $15.04▲ +24.71%▲ +25.11%$13.04 (+8.13%)
Showing 10 of 20

US Market Status

Market Open — Closes in 50m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 20, 2026